Tissue factor pathway inhibitor (TFPI) in disseminated intravascular coagulation: Low levels of the activated factor X-TFPI complex

Blood Coagulation and Fibrinolysis

Volumn 11, Issue 7, 2000, Pages 591-598

  Iversen, N ^a   Strekerud, F G ^a   Abildgaard, Ulrich ^a,b  

^a AKER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Activated factor X tissue factor pathway inhibitor complex; Disseminated intravascular coagulation; Inhibition of blood coagulation; Tissue factor pathway inhibitor

Indexed keywords

BLOOD CLOTTING FACTOR 10; FIBRIN MONOMER; THROMBIN ANTITHROMBIN COMPLEX; TISSUE FACTOR PATHWAY INHIBITOR; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLOOD ANALYSIS; BLOOD CLOTTING; BLOOD LEVEL; CONTROLLED STUDY; CORRELATION FUNCTION; DISSEMINATED INTRAVASCULAR CLOTTING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEASUREMENT; PRIORITY JOURNAL;

ADULT; ANTICOAGULANTS; COHORT STUDIES; DISSEMINATED INTRAVASCULAR COAGULATION; FACTOR XA; FEMALE; HUMANS; INFLAMMATION; LIPOPROTEINS; MALE; MIDDLE AGED; NEOPLASMS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PROTEIN BINDING; SEPSIS; STATISTICS, NONPARAMETRIC; THROMBOPHILIA;

EID: 0033761834     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200010000-00002     Document Type: Article

References (35)

1. Disseminated intravascular coagulation: Objective criteria for clinical and laboratory diagnosis and assessment of therapeutic response
2. Pathophysiology, clinical manifestations, and therapy of consumptive coagulopathy
3. Antithrombin acts as a negative acute phase protein as established with studies on HepG2 cells and in baboons
4. Studies on the inflammatory-coagulant axis in the baboon response to E. coli: Regulatory roles of proteins C, S, C4bBP and of inhibitors of tissue factor
5. Depletion of extrisic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: Evidence supporting a physiologic role for EPI as a natural anticoagulant
6. Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits of endotoxin-induced intravascular coagulation and the generalized Schwartzman reaction
7. The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningococcal disease
8. Extrinsic pathway inhibitor in postoperative/posttraumatic septicemia: Increased levels in fatal cases
9. Elevated levels of tissue factor pathway inhibitor in acute non-lymphoblastic leukemia patients with disseminated intravascular coagulation
10. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation
11. Changes in plasma tissue factor pathway inhibitor levels during the clinical course of disseminated intravascular coagulation
12. Inhibition of the tissue factor-factor VII complex: Involvement of factor Xa and lipoproteins
13. Purification and characterization of the lipoprotein-associated coagulation inhibitor from normal plasma
14. Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients
15. Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not possess anticoagulant function in tissue factor-induced coagulation in vitro
16. The lipoprotein-associated coagulation inhibitor that inhibits the factor VIIa-tissue factor complex, also inhibits factor Xa: Insight into its possible mechanism of action
17. Modifications of extrisic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/tissue factor: Evidence for a two-step model of inhibition
18. Probable regulation of factor VIIa-tissue factor and prothrombinase by factor Xa-TFPI and TFPI in vivo
19. Pre-operative factor Xa-TFPI and post-operative Venous thrombosis
20. Quantitation of TFPI-Xa complexes with the imubind TFPI-Xa ELISA: A precise test for onset of thrombophilia
21. Pathophysiologic and biochemical events in disseminated intravascular coagulation: Dysregulation of procoagulant and anticoagulant pathways
22. Chromogenic substrate assay of extrisic pathway inhibitor (EPI): Levels in the normal population and relation to cholesterol
23. Plasma antigen levels of the lipoprotein-associated inhibitor in patient samples
24. An enzyme linked immunosorption assay for tissue factor pathway inhibitor
25. A new immunoassay for soluble fibrin enables a more sensitive detection of the activation state of blood coagulation in vivo
26. D-dimer - History of the discovery, characterization and utility of this and other fibrin fragments
27. Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators
28. Acute release of tissue factor pathway inhibitor after in vivo thrombin generation in baboons
29. The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor
30. Elevated TFPI in malignant disease: Relation to cancer type and hypercoagulation
31. TGF-β1 and Xa-TFPI complex in plasma: High levels in solid tumor, but not in haematological malignancies
32. The extrinsic pathway inhibitor: A regulator of tissue factor-dependent blood coagulation
33. TFPI/Xa complexes and anticoagulant therapy
34. Determination of human thrombin-antithrombin III complex in plasma with a enzyme-linked immunosorbent assay
35. Molar antithrombin concentration in normal human plasma